PACBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.84+0.11 (+6.36%)
Close on Oct 19, 2026
- Market cap
- $571.61M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $135.76M | $136.15M | $183.87M | $108.70M | $113.51M | $65.42M | $77.74M | $66.36M | $80.03M | $64.61M | 84.8% | -0.3% |
| Consumable revenue | $81.94M | $70.37M | $63.42M | $59.98M | $52.18M | $31.14M | $32.62M | $37.86M | $41.40M | $23.65M | 51.2% | +16.4% |
| Instrument revenue | $53.82M | $65.78M | $120.45M | $48.72M | $61.32M | $34.28M | $45.13M | $28.49M | $38.63M | $40.96M | 33.6% | -18.2% |
| Service and other revenue | $24.25M | $17.87M | $16.65M | $19.61M | $17.01M | $13.47M | $13.15M | $12.27M | $13.44M | $13.97M | 15.2% | +35.7% |
| Collaboration [Member] | – | – | – | – | – | – | – | – | – | $12.13M | – | – |
| Contractual [Member] | – | – | – | – | – | – | – | – | – | $12.13M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $72.80M | $78.71M | $105.41M | $69.56M | – | – | – | – | – | – | 45.5% | -7.5% |
| United States | $69.70M | $75.30M | $100.50M | $66.80M | – | – | – | – | – | – | 43.6% | -7.4% |
| Europe, Middle East and Africa | $44.05M | $34.59M | $40.66M | $22.60M | – | – | – | – | – | – | 27.5% | +27.3% |
| Asia-Pacific | $43.16M | $40.71M | $54.45M | $36.15M | $35.72M | $22.55M | $26.61M | $29.07M | $38.80M | $18.71M | 27.0% | +6.0% |
| Asia [Member] | – | – | – | – | – | – | – | – | – | $19.90M | – | – |
| Europe, Middle East, and Africa | – | – | $40.66M | $22.60M | $30.27M | $19.07M | $19.60M | $13.96M | $14.03M | $21.13M | – | – |
| Americas | – | – | $105.41M | $69.56M | $64.52M | $37.28M | $44.68M | $35.60M | $40.64M | $50.87M | – | – |
From the segment and revenue-disaggregation notes of Pacific Biosciences Of California's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.